To determine the success of AIPAC it has to measured against other treatments in development for similar patient groups in MBC and the current SOC. Its not a case of what we “ perceive” to be good or bad numbers.
Results so far show wide ranging potential applications with the no side effects, which would provide significant commercial and competitive advantages to any BP company buying Immutep outright. Immutep is also the emerging leader in Lag3 technology. For all the above reasons, imo, BP will want the whole pie rather than sharing with others and there could be real competitive tension over Immutep assets.
If a BP funds our AIPAC ph3 and draws a large amount of investor interest towards Immutep, it may not suit their end game of acquisition at the lowest possible price, especially if they are planning to make a move within the next 6 -12 months, which imo would represent the best window for picking us up at a discount. A market correction could also happen within that time frame.
This is all just hypothetical musings. Unless a really compelling offer emerges we should plough on, imo, and fund our own ph3 if necessary.
IMM Price at posting:
51.0¢ Sentiment: Buy Disclosure: Held
(20min delay)